Cargando…

Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids

An acute exacerbation of idiopathic pulmonary fibrosis (AEIPF) is a potentially fatal complication of an already debilitating disease. Management is currently centred on delivering excellent supportive care and identifying reversible triggers. Despite growing international awareness and collaboratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Brereton, Christopher J., Jo, Helen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792795/
https://www.ncbi.nlm.nih.gov/pubmed/33447274
http://dx.doi.org/10.1183/20734735.0086-2020
_version_ 1783633865774989312
author Brereton, Christopher J.
Jo, Helen E.
author_facet Brereton, Christopher J.
Jo, Helen E.
author_sort Brereton, Christopher J.
collection PubMed
description An acute exacerbation of idiopathic pulmonary fibrosis (AEIPF) is a potentially fatal complication of an already debilitating disease. Management is currently centred on delivering excellent supportive care and identifying reversible triggers. Despite growing international awareness and collaboration, no effective therapies have been identified. Corticosteroids are often the mainstay of treatment; however, the evidence base for their use is poor. Here, we review our current understanding of the disease process and how to manage it, with a focus on the role of corticosteroid therapy.
format Online
Article
Text
id pubmed-7792795
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-77927952021-01-13 Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids Brereton, Christopher J. Jo, Helen E. Breathe (Sheff) Expert Opinion An acute exacerbation of idiopathic pulmonary fibrosis (AEIPF) is a potentially fatal complication of an already debilitating disease. Management is currently centred on delivering excellent supportive care and identifying reversible triggers. Despite growing international awareness and collaboration, no effective therapies have been identified. Corticosteroids are often the mainstay of treatment; however, the evidence base for their use is poor. Here, we review our current understanding of the disease process and how to manage it, with a focus on the role of corticosteroid therapy. European Respiratory Society 2020-09 /pmc/articles/PMC7792795/ /pubmed/33447274 http://dx.doi.org/10.1183/20734735.0086-2020 Text en Copyright ©ERS 2020 http://creativecommons.org/licenses/by-nc/4.0/Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Expert Opinion
Brereton, Christopher J.
Jo, Helen E.
Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
title Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
title_full Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
title_fullStr Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
title_full_unstemmed Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
title_short Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
title_sort acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
topic Expert Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792795/
https://www.ncbi.nlm.nih.gov/pubmed/33447274
http://dx.doi.org/10.1183/20734735.0086-2020
work_keys_str_mv AT breretonchristopherj acuteexacerbationsofidiopathicpulmonaryfibrosisandtheroleofcorticosteroids
AT johelene acuteexacerbationsofidiopathicpulmonaryfibrosisandtheroleofcorticosteroids